TIGIT activity
TIGIT-Ig
TIGIT therapy
Blockage of TIGIT
different anti-TIGIT mAbs
various tumors
TILs
important checkpoint inhibitory receptor
various immune cells
Cancer immunotherapy drugs
cell activity
cancer treatment
increased T
inhibited tumor growth
immune-related therapies
tumor infiltrating lymphocytes
POC grant TIGITtherapy
BacNK ERC advanced grant
overall oncology drugs market
Natural Killer
expression
testing
promising advancements
Nectin2
main ligands
PVR
PD
combination
past decade
bio pharma companies
group